Search

Recent studies have suggested that puerarin may impede osteoclastogenesis and facilitate bone regeneration, in addition to attenuating tissue inflammation. The present study investigated the therapeutic effects of puerarin on inflammatory responses and monocyte recruitment in in vitro and in vivo osteoarthritis (OA) models. Puerarin treatment increased the proliferation of OA chondrocytes, as determined by Cell Counting Kit-8 assay. In addition, the present results suggested that puerarin suppressed the interleukin-1β-induced production of inflammatory cytokines in OA chondrocytes and monocytes/macrophages, as assessed by ELISA. In a mouse model of mono-iodoacetate-induced OA, the present histological analyses suggested that administration with puerarin attenuated the inflammatory profile of OA joints and reduced cartilage destruction. Using flow cytometry, a decreased number of myeloid-derived C-C chemokine receptor 2+/lymphocyte Ag 6C+ monocytes was identified in the blood of OA mice treated with puerarin compared with control OA mice. Furthermore, quantitative real-time polymerase chain reaction analysis suggested that puerarin treatment decreased C-C chemokine ligand 2 expression in arthritic tissues. Collectively, the results suggested that puerarin treatment limited the recruitment of inflammatory monocytes. In summary, the present study provided pre-clinical evidence that puerarin may serve as a potential target in the treatment of OA. [ABSTRACT FROM AUTHOR]

The creation of a catalytic method that possesses high activity and effective reusability for the oxidative cleavage of vegetable oils and their derivatives to prepare bio-based oxo-chemicals is a challenge. This work introduces a “release and capture” catalytic system consisting of H2O2, WO3 and mesoporous SnO2. This system was intended to promote catalyst reusability in the oxidative cleavage of methyl 9,10-epoxystearate (ME) to the corresponding aldehydes. No organic solvent was used in the reaction. The reaction temperature, molar ratio of ME/WO3/H2O2, and reaction time were optimized to 70 °C, 1/0.017/1.3, and 20 min, respectively. Under these conditions, complete ME conversion and 80% aldehyde yield were obtained. The hot filtration experiment and ICP-MS analysis confirmed the leaching of tungsten. Mesoporous SnO2 did not affect the ME conversion and aldehyde yield, but effectively adsorbed the leached tungsten. The catalyst in this system showed no significant decrease in activity after being reused ten times. [ABSTRACT FROM AUTHOR]

At present, the utilization of grease has attracted more and more attention. This article presents a simple method that efficiently cleaves methyl oleate‐derived methyl 9,10‐epoxystearate (a) to give high yields of methyl 9‐oxononanoate (d) with nonanal (c) as co‐product. A WO3/MCM‐41 catalyst is prepared via direct mixed‐gel synthesis. The catalyst is tested in the oxidative cleavage of a to produce d which can be used as a polymer precursor or an important feedstock. The effects of WO3 loading, temperature, time, H2O2/a molar ratio, catalyst/a weight ratio, and t‐BuOH/a weight ratio on the a conversion and d yield are examined using single‐factor experiments. The optimal reaction conditions are determined by orthogonal experiments. The optimal WO3 loading, temperature, time, H2O2/a molar ratio, catalyst/a weight ratio, and t‐BuOH/a weight ratio are 35%, 80 °C, 20 min, 1.3, 0.04, and 0.5, respectively. Under these conditions, the a conversion and d yield reach 99.4 and 78.4%, respectively. In addition, the catalyst shows no significant decrease in activity after being reused three times. Moreover, the reaction mechanism is studied based on the product distribution over time. Practical Applications: Few studies on methyl 9,10‐epoxystearate used as the raw material to give methyl 9‐oxononanoate and nonanal are found. Because the ethylene oxide bond is more unstable than the carbon–carbon double bond, the oxidative cleavage of methyl 9,10‐epoxystearate is easier than cleavage of methyl oleate that allows the oxidative cleavage to be done under milder conditions. Methyl 9‐oxononanoate can be converted to a monomer of high‐value polymers and is also an important feedstock in the production of chemicals. The co‐product nonanal is a natural spice which can be used in the fragrance industry. The results show that the reaction time is short and methyl 9‐oxononanoate yield is high under mild reaction conditions. The method in this study can also be widely used in other oxidative cleavage reactions of epoxides. Methyl 9,10‐epoxystearate is used as the raw material to produce methyl 9‐oxononanoate with nonanal as co‐product using WO3/MCM‐41 as catalyst and H2O2 as oxidant. [ABSTRACT FROM AUTHOR]

To maintain the integrity of electrodes via conductive binders plays a critical role for Li-ion batteries. In this letter, polyaspartic acid (PASP) was synthesized and used as a novel water-soluble binder for an LiFePO 4 (LFP) cathode. At a 1 C current density, this LiFePO 4 cathode had a discharge specific capacity of 152 mAh g−1 and retained close to 100% of the initial specific capacity after 40 cycles. Furthermore, this LiFePO4 cathode also maintained a high specific capacity of 122 mAh g−1 at 5C rate. The results of electrochemical impedance spectroscopy and scanning electron microscopy indicated that the layer of PASP that was coated on the LFP electrode, which maintained the integrity of the conductive network and reduced the Li + diffusion path length of the LFP electrode. Based on these properties, PASP could be a prospective binder for LFP cathodes. [Display omitted] • PASP contains both nonpolar and polar groups. And PASP is a fluorine-free binder. • PASP as water-based binder is safe, environmentally friendly for LFP cathnod. • PASP is on the LFP particle to maintained the integrity of the conductive network. [ABSTRACT FROM AUTHOR]

• Sargassum horneri is utilized as catalyst for esterification reactions. • The successful grafting of –SO 3 H groups is confirmed by FT-IR and XPS. • The oleic acid conversion of >96% was obtained at optimal conditions. • The catalyst shows remarkable regenerability. A solid acid catalyst prepared by sulfonated Sargassum horneri carbon was utilized for the esterification reaction of oleic acid and methanol. The formed amorphous carbon layers during carbonization and the access of sulfonic acid groups during sulfonation can catalyze the esterification reaction for biodiesel preparation efficiently. The catalyst was characterized by various methods to investigate its physical and chemical properties. With carbonization at 300 °C for 2 h followed by sulfonation at 90 °C for 5 h, the catalyst reached acid density of 1.40 mmol/g. The catalyst dosage, methanol/oleic acid (molar ratio), reaction temperature, and reaction time were optimized to 10 wt%, 15:1, 70 °C, and 3 h, respectively. Under the optimal condition, the conversion of oleic acid reached 96.4%. Additionally, the catalyst was regenerated after four cycles, with the conversion of oleic acid still reaching 95.4%. [ABSTRACT FROM AUTHOR]

Lenvatinib plus pembrolizumab or everolimus have considerable clinical benefits. However, it is controversial whether the high-cost combination regimen will be approved by the guidelines and widely used in clinical practice. Based on current prices, lenvatinib plus pembrolizumab is a cost-effective treatment option. Our conclusions provide objective data reference for clinicians when making clinical decisions, individual treatment of patients, and reference for national health insurance decision-making. Introduction: The CLEAR trial indicated that survival benefits were generated with lenvatinib plus pembrolizumab (LP) or everolimus (LE) than with sunitinib for advanced renal cell carcinoma (aRCC). However, the high cost of immuno-target and dual-targeted treatment, we assessed the costeffectiveness of lenvatinib plus pembrolizumab or everolimus in the first-line setting for treatment of patients with aRCC from the United States (US) payers' perspective. Materials and Methods: A comprehensive Markov model was developed to evaluate the cost and effectiveness of LP or LE in first-line therapy for aRCC. We estimated life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Utility values and direct costs related to the treatments were gathered from the published studies. Then, one-way and probabilistic sensitivity analyses were performed. Additional subgroup analyses were considered. Results: Treatment with LP and LE provided an additional 0.67 QALYs (0.62 LYs) and 0.66 QALYs (0.90 LYs) compared with sunitinib, resulting in ICER of $131,656 per QALY and 201,928 per QALY, respectively. The most influential factor in this model was the cost of pembrolizumab with LP. Probabilistic sensitivity analysis showed there was a 58.97% and 28.91% probability that LP and LE were cost-effective at WTP values of $150,000 per QALY in the US. Subgroup analyses demonstrated that LP was more cost-effective for patients from Western Europe and North America, intermediate risk of the International risk group of Metastatic Renal Cell Carcinoma Database Consortium (IMDC), favorable and intermediate risk group of Memorial Sloan Kettering Cancer Center (MSKCC) and PD-L1 combined positive score greater than or equal to 1%. Conclusion: From the perspective of the US payer, LP is a cost-effective option as first-line treatment for patients with aRCC at a WTP threshold of $150,000 per QALY, but LE is the opposite. [ABSTRACT FROM AUTHOR]

Background: Due to the adverse effects of cemented hip arthroplasty, uncemented stems with hydroxyapatite (HA) coating reduces these risks and enhanced integration. The concept of an extensive HA coating for the fixation of a tapered femoral stem (Corail) was introduced, which can achieve durable biological fixation and preserve normal periprosthetic bone activity. Here we describe the clinical and radiological outcome in patients with the Corail stem. Methods: 92 total hip replacements in 81 patients using the Corail stem were followed-up. 47 patients were women, and the mean age at surgery was 62.9 ± 8.7 (34-71) years. The indications included: osteoarthritis of the hip (71.1%), avascular necrosis (13.6%), femur neck fractures in elderly (9.7%) and post-traumatic osteoarthritis (6.8%). Findings: Eight patients died during follow-up. The revision was only found in two patients due to line wear and resulted in an 10-year Kaplan-Meier estimated overall survival rate of 97.83%. The clinical results were good, with a mean Harris hip score of 92.3 ± 5.6 (72-100). The mean total Merle d'Aubigné and Postel score was 6.8 ± 0.5 pre-operatively and 16.1 ± 1.4 at latest follow-up. All unrevised implants were radiographically stable, with a mean liner wear of 0.07 mm/year. Conclusion: This long-term analysis confirmed the durability of the functional and radiographic results. Our findings suggest the long-term results of Corail HA-coated stem are more satisfactory which is preferable to any other system. [ABSTRACT FROM AUTHOR]

Eph receptors play important roles in the development of cancer. The present study aimed to investigate the expression of EphA1 and its clinicopathologic significance in esophageal squamous cell carcinoma ( ESCC). The expression levels of the EphA1 transcript and protein were compared between ESCC and matched normal mucosa in the same patient. High expression levels of the EphA1 transcript and protein were detected in 25.6% (21/82) and 23.2% (19/82) of tumors compared with matched normal mucosa. The up-regulation of EphA1 transcript in tumors was positively associated with differentiation (p = 0.002), disease stage (p = 0.034), and lymph node metastasis (p = 0.042). Increased expression of EphA1 protein in tumors was more often observed in patients with well-differentiated tumors (p = 0.004), lymph node metastasis (p = 0.028), and advanced tumor stage (p = 0.008). EphA1 protein expression was detected in intraepithelial neoplasias as well. Decreased expression of EphA1 protein was detected in 65.2% (15/23) of samples with low-grade neoplasia and in 85.3% (8/15) of samples with high-grade intraepithelial neoplasia. Increased staining of EphA1 protein was not detected in low-grade intraepithelial neoplasia samples, but was detected in 21.3% (2/15) of high-grade intraepithelial neoplasia samples. Taken together, our results show that EphA1 appears to be a differentiation marker for esophageal squamous cells, and its increased expression is positively associated with lymph node metastasis and advanced disease stage. [ABSTRACT FROM AUTHOR]